Original Article

You have full text access to this OnlineOpen article

Development of prognostic factors and survival in cutaneous melanoma over 25 years

An analysis of the Central Malignant Melanoma Registry of the German Dermatological Society†

  1. Petra G. Buettner Ph.D.1,
  2. Ulrike Leiter M.D.2,
  3. Thomas K. Eigentler M.D.2,
  4. Claus Garbe M.D.1,2,‡,*

Article first published online: 3 JAN 2005

DOI: 10.1002/cncr.20816

Issue

Cancer

Cancer

Volume 103, Issue 3, pages 616–624, 1 February 2005

Additional Information

How to Cite

Buettner, P. G., Leiter, U., Eigentler, T. K. and Garbe, C. (2005), Development of prognostic factors and survival in cutaneous melanoma over 25 years. Cancer, 103: 616–624. doi: 10.1002/cncr.20816

Author Information

  1. 1

    School of Public Health and Tropical Medicine, James Cook University, Townsville, Australia

  2. 2

    Section of Dermatologic Oncology, Department of Dermatology, Skin Cancer Program, Central Malignant Melanoma Registry of the German Dermatological Society, Eberhard-Karls-University of Tuebingen, Tuebingen, Germany

  1. ‡

    Fax: (011) 0049-07071-295187

*Department of Dermatology, Eberhard-Karls-University of Tuebingen, Liebermeisterstrasse 25, D-72076 Tuebingen, Germany

  1. †

    The following Departments of Dermatology were major contributors (more than 500 cases) to the Central Malignant Melanoma Registry of the German Dermatological Society: University of Berlin (Charité) (Chair: W. Sterry); Free University of Berlin (Chair: C.E. Orfanos); Berlin-Neukölln (Chair: P. Kohl); Chemnitz (Chair: J. Koch); Dortmund (Chair: P. Frosch); Dresden-Friedrichstadt (Chair: U. Wollina); University of Dresden (Chair: M. Meurer); Erfurt (Chair: R. Linse); University of Erlangen (Chair: G. Schuler); University of Essen (Chair: S. Graabe); University of Freiburg (Chair: L. Bruckner-Tudermann); Gera (Chair: J. Meyer); University of Göttingen (Chair: Ch. Neumann); University of Graz (Chair: H. Kerl); University of Greifswald (Chair: M. Jünger); University of Halle (Chair: W. Marsch); University of Hamburg (Chair: I. Moll); Hamburg-St. Georg (Chair: C. Sander); Hildesheim (Chair: H. Tronnier); University of Heidelberg (Chair: A. Enk); University of Heidelberg/Mannheim (Chair: S. Goerdt); University of Homburg (Chair: W. Tilgen); University of Jena (Chair: P. Elsner); Kassel (Chair: R. Rompel); University of Kiel (Chair: T. Schwarz); Krefeld (Chair: S. Wassilew); University of Leipzig (Chair: J. Simon); University of Lübeck (Chair: D. Zillikens); University of Magdeburg (Chair: H. Gollnick); Minden (Chair: R. Stadler); University of Munich (Chair: G. Plewig); University of Münster (Chair: Th. Luger); Nürnberg (Chair: E. Paul); University of Tuebingen (Chair: M. Röcken); University of Ulm (Chair: K. Scharfetter-Kochanek); Wiesbaden (Chair: J. Metz); University of Würzburg (Chair: E.B. Bröcker); and the University of Zürich (Chair: G. Burg).

Publication History

  1. Issue published online: 20 JAN 2005
  2. Article first published online: 3 JAN 2005
  3. Manuscript Accepted: 11 OCT 2004
  4. Manuscript Revised: 1 JUL 2004
  5. Manuscript Received: 27 APR 2004

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (246K)

REFERENCES

  • 1
    Grin-Jorgensen CM, Rigel DS, Friedman RJ. The worldwide incidence of malignant melanoma. In: BalchCM, HoughtonAN, MiltonGW, SoberAJ, SoongS-J, editors. Cutaneous melanoma: clinical management and treatment results worldwide. 2nd edition. Philadelphia: J.B. Lippincott, 1992: 27–39.
  • 2
    Devesa SS, Silverman DT, Young JL Jr., et al. Cancer incidence and mortality trends among whites in the United States, 1947-84. J Natl Cancer Inst. 1987; 79: 701–770.
  • 3
    Hakulinen T, Andersen A, Malker B, Pukkala E, Schou G, Tulinius H. Trends in the cancer incidence in the Nordic countries. A collaborative study of the five Nordic Cancer Registries. Acta Pathol Microbiol Immunol Scand Suppl. 1986; 288: 1–151.
  • 4
    De Vries E, Bray FI, Coebergh JW, Parkin DM. Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997: rising trends in incidence and mortality but recent stabilizations in western Europe and decreases in Scandinavia. Int J Cancer. 2003; 107: 119–126.
    Direct Link:
  • 5
    Gaudette LA, Gao RN. Changing trends in melanoma incidence and mortality. Health Rep. 1998; 10: 29–41.
  • 6
    Bulliard JL, Cox B, Semenciw R. Trends by anatomic site in the incidence of cutaneous malignant melanoma in Canada, 1969-93. Cancer Causes Control. 1999; 10: 407–416.
  • 7
    Dennis LK, White E, Lee JA.. Recent cohort trends in malignant melanoma by anatomic site in the United States. Cancer Causes Control. 1993; 4: 93–100.
  • 8
    Hall HI, Miller DR, Rogers JD, Bewerse B. Update on the incidence and mortality from melanoma in the United States. J Am Acad Dermatol. 1999; 40: 35–42.
  • 9
    Bulliard JL, Cox B. Cutaneous malignant melanoma in New Zealand: trends by anatomical site, 1969-1993. Int J Epidemiol. 2000; 29: 416–423.
  • 10
    Marrett LD, Nguyen HL, Armstrong BK. Trends in the incidence of cutaneous malignant melanoma in New South Wales, 1983-1996. Int J Cancer. 2001; 92: 457–462.
    Direct Link:
  • 11
    La Vecchia C, Lucchini F, Negri E, Levi F. Recent declines in worldwide mortality from cutaneous melanoma in youth and middle age. Int J Cancer. 1999; 81: 62–66.
    Direct Link:
  • 12
    Severi G, Giles GG, Robertson C, Boyle P, Autier P. Mortality from cutaneous melanoma: evidence for contrasting trends between populations. Br J Cancer. 2000; 82: 1887–1891.
  • 13
    Stang A, Jockel KH. Changing patterns of skin melanoma mortality in West Germany from 1968 through 1999. Ann Epidemiol. 2003; 13: 436–442.
  • 14
    Schuz J, Schon D, Batzler W, et al. Cancer registration in Germany: current status, perspectives and trends in cancer incidence 1973-93. J Epidemiol Biostat. 2000; 5: 99–107.
  • 15
    The network of German population-based registries. Available from URL: http://www.rki.de/GBE/KREBS/BROSCHUERE2002/BROSCHUERE2002.HTM [accessed June 30, 2004].
  • 16
    Balch CM, Soong SJ, Shaw, HM, Milton GW. An analysis of prognostic factors of 8500 patients with cutaneous melanoma. In: BalchCM, HoughtonAN, MiltonGW, SoberAJ, SoongS-J, editors. Cutaneous melanoma: clinical management and treatment results worldwide. 2nd edition. Philadelphia: J.B. Lippincott, 1992: 165–187.
  • 17
    Morton DL, Davtyan DG, Wanek LA, Foshag LJ, Cochran AJ. Multivariate analysis of the relationship between survival and the microstage of primary melanoma by Clark level and Breslow thickness. Cancer. 1993; 71: 3737–3743.
    Direct Link:
  • 18
    Garbe C, Buttner P, Bertz J, et al. Primary cutaneous melanoma: identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer. 1995; 75: 2484–2491.
    Direct Link:
  • 19
    Balch CM, Soong S-J, Gershenwald JE, et al.et al. Prognostic factors and analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001; 19: 3622–3634.
  • 20
    Kittler H, Binder M, Wolff K, Pehamberger H. A ten-year analysis of demographic trends for cutaneous melanoma: analysis of 2501 cases treated at the University Department of Dermatology in Vienna (1990-1999). Wien Klin Wochenschr. 2001; 113: 321–327.
  • 21
    Thorn M, Ponten F, Bergstrom R, Sparen P, Adami HO. Trends in tumour characteristics and survival of malignant melanoma 1960-84: a population-based study in Sweden. Br J Cancer. 1994; 70: 743–748.
  • 22
    Levi F, Randimbison L, La Vecchia C, Te VC, Franceschi S. Prognostic factors for cutaneous malignant melanoma in Vaud, Switzerland. Int J Cancer. 1998; 78: 315–319.
    Direct Link:
  • 23
    Mansson-Brahme E, Johansson H, Larsson O, Rutqvist LE, Ringborg U. Trends in incidence of cutaneous malignant melanoma in a Swedish population 1976-1994. Acta Oncol. 2002; 41: 138–146.
  • 24
    Balch CM, Soong S-J, Shaw HM, et al. Changing trends in the clinical and pathological features of melanoma. In: BalchCM, HoughtonAN, MiltonGW, SoberAJ, SoongS-J, editors. Cutaneous melanoma: clinical management and treatment results worldwide. 2nd edition. Philadelphia: J.B. Lippincott, 1992: 40–45.
  • 25
    Dennis LK. Analysis of the melanoma epidemic, both apparent and real: data from the 1973 through 1994 Surveillance, Epidemiology, and End Results program registry. Arch Dermatol. 1999; 135: 275–280.
  • 26
    Jemal A, Devesa SS, Hartge P, Tucker MA. Recent trends in cutaneous melanoma incidence among whites in the United States. J Natl Cancer Inst. 2001; 93: 678–683.
  • 27
    Garbe C, McLeod GRC, Buettner PG. Time trends of cutaneous melanoma in Queensland, Australia and Central Europe. Cancer. 2000; 89: 1269–1278.
    Direct Link:
  • 28
    Hursthouse MW. Melanoma incidence and trends in the Nelson-Marlborough area of New Zealand. N Z Med J. 1992; 105: 424–425.
  • 29
    Little JH, Holt J, Davis N. Changing epidemiology of malignant melanoma in Queensland. Med J Aust. 1980; 1: 66–69.
  • 30
    Kolmel KF, Kulle B, Lippold A, Seebacher C. Survival probabilities and hazard functions of malignant melanoma in Germany 1972-1996, an analysis of 10433 patients. Evolution of gender differences and malignancy. Eur J Cancer. 2002; 38: 1388–1394.
  • 31
    Illig L, McCann-Roos U, Klaubert EW, et al. Public education in recognizing melanoma [review] [in German]. Z Hautkr. 1989; 64: 537–538, 543–546, 551–563.
  • 32
    Hoffmann K, Dirschka T, Schatz H, Segerling M, Tiemann T, Hoffmann A. A local education campaign on early diagnosis of malignant melanoma. Eur J Epidemiol. 1993; 9: 591–598.
  • 33
    Pfahlberg A, Gefeller O, Koelmel KF. Public awareness of malignant melanoma risk factors in Germany. J Epidemiol Commun Health. 1997; 51: 698–700.
  • 34
    Kolmel KF, Pfahlberg A, Gefeller O. Prevention of melanoma by sun protective measures in childhood. Temporal changes in awareness of parents. Hautarzt. 1997; 48: 391–396.
  • 35
    MacKie RM, Hole D, Hunter JA, et al. Cutaneous malignant melanoma in Scotland: incidence, survival, and mortality, 1979-94. The Scottish Melanoma Group. Br Med J. 1997; 315: 1117–1121.
  • 36
    Stang A, Stang K, Stegmaier C, Hakulinen T, Jockel KH. Skin melanoma in Saarland: incidence, survival and mortality 1970-1996. Eur J Cancer Prev. 2001; 10: 407–415.
  • 37
    MacLennan R, Green AC, McLeod GR, Martin NG. Increasing incidence of cutaneous melanoma in Queensland, Australia. J Natl Cancer Inst. 1992; 84: 1427–1432.
  • 38
    Streetly A, Markowe H. Changing trends in the epidemiology of malignant melanoma: gender differences and their implications for public health. Int J Epidemiol. 1995; 24: 897–907.
  • 39
    McGregor SE, Birdsell JM, Grace MA, Jerry LM, Hill GB, Paterson AHG. Cutaneous malignant melanoma in Alberta: 1967–1976. Cancer. 1983; 52: 755–761.
    Direct Link:
  • 40
    MacKie R, Hunter AA, Aitchison TC, Hole D, McLaren K, Rankin R. Cutaneous malignant melanoma, Scotland, 1979–1989. Lancet. 1992; 339: 971–975.
  • 41
    Magnus K. Habits of sun exposure and risk of malignant melanoma: an analysis of incidence rates in Norway 1955–1977 by cohort, sex, age, and primary tumor site. Cancer. 1981; 48: 2329–2335.
    Direct Link:
  • 42
    Armstrong BK. Epidemiology of melanoma: intermittent or total accumulative exposure to the sun? J Dermatol Surg Oncol. 1988; 14: 835–849.
  • 43
    Armstrong BK, English DR. Epidemiologic studies. In: BalchCM, HoughtonAN, MiltonGW, SoberAJ, SoongS-J, editors. Cutaneous melanoma: clinical management and treatment results worldwide. 2nd edition. Philadelphia: J.B. Lippincott, 1992: 12–26.
View Full Article (HTML) Get PDF (246K)